公开(公告)号：EP3418297A1

公开(公告)日：2018-12-26

申请号：EP18174008.5

申请日：2006-12-06

申请人： KYOTO UNIVERSITY

发明人： YAMANAKA, Shinya

IPC分类号： C07K14/47

CPC分类号： C07K14/4702 ,  C12N5/0696 ,  C12N2501/60 ,  C12N2501/602 ,  C12N2501/603 ,  C12N2501/604 ,  C12N2501/605 ,  C12N2501/606 ,  C12N2510/00 ,  C12N2799/027

摘要： There is provided a nuclear reprogramming factor for a somatic cell, which comprises a gene product of each of the following three kinds of genes: an Oct family gene, a Klf family gene, and a Myc family gene, as a means for inducing reprogramming of a differentiated cell to conveniently and highly reproducibly establish an induced pluripotent stem cell having pluripotency and growth ability similar to those of ES cells without using embryo or ES cell.

公开(公告)号：EP3350316A1

公开(公告)日：2018-07-25

申请号：EP16775091.8

申请日：2016-09-14

申请人： Stichting Katholieke Universiteit

发明人： DOLSTRA, Harmen

IPC分类号： C12N5/0783 ,  A61K35/17

CPC分类号： C12N5/0646 ,  A61K35/17 ,  A61P35/00 ,  C12N2500/46 ,  C12N2501/145 ,  C12N2501/20 ,  C12N2501/2307 ,  C12N2501/2312 ,  C12N2501/2315 ,  C12N2501/26 ,  C12N2501/60 ,  C12N2506/11

摘要： The present invention relates to the field of medicine, specifically the field of treatment of cancer. More specifically, the invention relates to a method for the ex vivo production of a population of highly functional NK cells from CD34-positive cells, to a population of highly functional NK cells obtained and to the use of such population of highly functional NK cells for adoptive cell therapy.

公开(公告)号：EP3344757A1

公开(公告)日：2018-07-11

申请号：EP15774515.9

申请日：2015-09-04

申请人： Universita' Degli Studi Di Padova

发明人： PICCOLO, Stefano ,  AZZOLIN, Luca ,  PANCIERA, Tito ,  CORDENONSI, Michelangelo ,  ZANCONATO, Francesca ,  FUJIMURA, Atsushi

IPC分类号： C12N5/074 ,  C12N5/0797 ,  C12N5/071

CPC分类号： C12N5/0607 ,  A61K35/28 ,  A61K38/00 ,  C07K14/4705 ,  C12N5/0623 ,  C12N5/0631 ,  C12N5/0678 ,  C12N9/1025 ,  C12N2501/60 ,  C12N2506/08 ,  C12N2506/095 ,  C12N2506/22 ,  C12N2510/00

摘要： The present invention provides a method for generating somatic stem cells out of differentiated cells, somatic stem cells obtained by this method and a vector or composition for use in this method.

公开(公告)号：EP3327117A1

公开(公告)日：2018-05-30

申请号：EP18150705.4

申请日：2006-12-08

申请人： Academisch Medisch Centrum bij de Universiteit van Amsterdam ,  AIMM Therapeutics B.V.

发明人： Spits, Hergen ,  Scheeren, Ferenc Alexander ,  Beaumont, Tim ,  Diehl, Sean Andrew

IPC分类号： C12N5/0781 ,  C12N5/10 ,  C07K16/00 ,  C12P21/08

CPC分类号： C12N5/0635 ,  C07K16/00 ,  C12N2501/23 ,  C12N2501/231 ,  C12N2501/2321 ,  C12N2501/52 ,  C12N2501/60 ,  C12N2502/99 ,  C12N2510/02 ,  C12N2510/04

摘要： The invention provides a method for influencing the stability of an antibody producing cell, comprising directly or indirectly influencing the amount of BCL6 and/or Blimp-1 expression product within said antibody producing cell. Stable antibody producing cells and cell lines are also provided, as well as methods for producing antibodies using such cells and/or cell lines.

公开(公告)号：EP3307873A2

公开(公告)日：2018-04-18

申请号：EP16808311.1

申请日：2016-06-09

申请人： The Regents of the University of California

发明人： ZOVEIN, Ann, C.

IPC分类号： C12N5/00 ,  C12N5/0789

CPC分类号： C12N15/85 ,  C12N5/0647 ,  C12N2501/105 ,  C12N2501/11 ,  C12N2501/115 ,  C12N2501/125 ,  C12N2501/145 ,  C12N2501/2303 ,  C12N2501/2306 ,  C12N2501/26 ,  C12N2501/60 ,  C12N2506/28 ,  C12N2510/00

摘要： The disclosure relates to compositions comprising hematopoietic cells and methods of using the same. The disclosure also relates to methods of reprogramming endothelial cells into hematopoietic cells by exposing the endothelial cells to at least one hematopoietic effector.

公开(公告)号：EP2707479B1

公开(公告)日：2018-01-10

申请号：EP12785169.9

申请日：2012-05-11

申请人： The United States of America, as represented by The Secretary, Department of Health and Human Services ,  Elixirgen, LLC

发明人： KO, Minoru, S.H. ,  HIRATA, Tetsuya

IPC分类号： C12N5/00 ,  C12N15/00 ,  C12N15/63 ,  C12N5/10 ,  C12N15/85 ,  C12N5/074

CPC分类号： C12N5/0696 ,  C07H21/04 ,  C07K14/47 ,  C12N5/0606 ,  C12N15/63 ,  C12N15/79 ,  C12N15/85 ,  C12N15/86 ,  C12N2501/60 ,  C12N2501/602 ,  C12N2501/603 ,  C12N2501/604 ,  C12N2501/605 ,  C12N2501/606 ,  C12N2501/608 ,  C12N2506/00 ,  C12N2506/1307

摘要： Disclosed herein is the finding that Zscan4 is an early embryonic factor that facilitates cellular reprogramming. In particular, Zscan4 can replace the oncogenic reprogramming factor c-Myc to produce induced pluripotent stem cells when co-expressed with Klf4, Oct4 and Sox2. In addition, several Zscan4-dependent genes were identified that promote iPSC formation when co-expressed with known reprogramming factors. Thus, the present disclosure provides an ex vivo method of producing an iPS cell by reprogramming of a somatic cell. The method includes contacting the somatic cell with a Zscan4, or a Zscan4-dependent gene, and at least one reprogramming factor. Also provided are iPS cells produced by the disclosed method and non-human animals generated from such iPS cells.

公开(公告)号：EP3224352A1

公开(公告)日：2017-10-04

申请号：EP15801762.4

申请日：2015-11-25

申请人： IEO - Istituto Europeo di Oncologia Srl ,  I.R.C.C.S. Casa Sollievo Della Sofferenza ,  Universita' degli Studi di Milano

发明人： TESTA, Giuseppe ,  ATASHPAZGARGARI, Sina ,  ADAMO, Antonio ,  GERMAIN, Pierre-Luc ,  MERLA, Giuseppe ,  D'AGOSTINO, Giuseppe ,  ZANELLA, Matteo

IPC分类号： C12N5/10 ,  C12N5/079 ,  C12Q1/02 ,  A61K31/00 ,  A61P25/00

CPC分类号： C12N5/0696 ,  A61K31/135 ,  A61K31/421 ,  C12N2501/06 ,  C12N2501/115 ,  C12N2501/13 ,  C12N2501/60 ,  C12N2501/602 ,  C12N2501/603 ,  C12N2501/604 ,  C12N2501/606 ,  C12N2501/608 ,  C12N2501/727 ,  C12N2503/00 ,  C12N2503/02 ,  C12N2506/1307 ,  C12N2510/00 ,  C12N2740/15041 ,  C12Q1/6881 ,  C12Q1/6883 ,  C12Q1/6897 ,  C12Q2600/158 ,  G01N33/5058 ,  G01N33/5073

摘要： The present invention relates to iPSC produced from fibroblast obtained from a subject affected by a neurodevelopmental disorder entailing intellectual disability (ID) and/or a disorder belonging to the Autism Spectrum Disorder (ASD) and/or Schizophrenia (SZ) and uses thereof. The present invention also relates to a cortical neural progenitor cell or a terminally differentiated cortical glutamatergic or gabaergic neuronal cell or a neural crest stem cell line, a mesenchymal stem cell line produced from the iPSC or iPSC line. The invention also relates to method for identifying a compound for the treatment and/or prevention of a neurodevelopmental disorder entailing intellectual disability (ID) and/or a disorder belonging to the Autism Spectrum Disorder (ASD) and/or Schizophrenia (SZ) and to a LSD1 inhibitor or a HDAC2 inhibitor for use in the treatment of such disorders.

摘要翻译： 本发明涉及从受到患有智力障碍（ID）的神经发育障碍和/或属于自闭症障碍（ASD）和/或精神分裂症（SZ）的障碍影响的受试者获得的成纤维细胞产生的iPSC及其用途。 本发明还涉及由iPSC或iPSC系产生的皮质神经祖细胞或终末分化的皮质谷氨酸能或gabaergic神经元细胞或神经嵴干细胞系，间充质干细胞系。 本发明还涉及鉴定用于治疗和/或预防患有智力障碍（ID）和/或属于自闭症谱系障碍（ASD）和/或精神分裂症（SZ）的障碍的神经发育病症的化合物的方法，以及 用于治疗此类病症的LSD1抑制剂或HDAC2抑制剂。

公开(公告)号：EP2300611B1

公开(公告)日：2017-08-09

申请号：EP09763816.7

申请日：2009-06-15

申请人： Whitehead Institute for Biomedical Research

发明人： JAENISCH, Rudolf ,  CAREY, Bryce Woodbury

IPC分类号： A01K67/027 ,  G01N33/50 ,  C12N5/0735 ,  C12N15/79 ,  C12N15/85 ,  C12N15/86 ,  C12N5/10 ,  C12N5/074

CPC分类号： C12N15/86 ,  A01K67/0271 ,  C07K14/4705 ,  C12N5/0606 ,  C12N5/0696 ,  C12N15/79 ,  C12N15/85 ,  C12N2501/60 ,  C12N2501/602 ,  C12N2501/603 ,  C12N2501/604 ,  C12N2501/605 ,  C12N2501/606 ,  C12N2501/608 ,  C12N2506/11 ,  C12N2506/115 ,  C12N2510/00 ,  C12N2740/15041 ,  C12N2740/15043 ,  C12N2740/16043 ,  C12N2799/027 ,  C12N2800/108 ,  C12N2840/203 ,  G01N33/5008

公开(公告)号：EP3196295A1

公开(公告)日：2017-07-26

申请号：EP16152655.3

申请日：2016-01-25

申请人： Albert-Ludwigs-Universität Freiburg

发明人： LIENKAMP, Soeren ,  KAMINSKI, Michael ,  ARNOLD, Sebastian ,  WALZ, Gerd

IPC分类号： C12N5/071

CPC分类号： C12N5/0686 ,  C12N2501/60 ,  C12N2506/1307 ,  C12N2510/00 ,  C12N2513/00

摘要： The present invention relates to a method for producing renal cells, comprising overexpressing Emx2, Hnf1b, Hnf4a and Pax8 in fibroblasts.

摘要翻译： 本发明涉及生产肾细胞的方法，其包括在成纤维细胞中过表达Emx2，Hnf1b，Hnf4a和Pax8。

公开(公告)号：EP2714896B1

公开(公告)日：2017-06-21

申请号：EP12788729.7

申请日：2012-05-23

申请人： Ajou University Industry-Academic Cooperation Foundation

发明人： SUH, Hae Young ,  KIM, Sung Soo ,  YOO, Seung Wan ,  LEE, Young Don

IPC分类号： C12N5/074 ,  C12N5/0775 ,  C12N5/10 ,  C12N15/861 ,  A61K35/28

CPC分类号： C12N15/85 ,  A61K35/28 ,  A61K35/30 ,  C12N5/0663 ,  C12N15/86 ,  C12N2501/12 ,  C12N2501/60 ,  C12N2510/00

摘要： The present invention relates to an adult stem cell line introduced with an HGF gene and a neurogenic transcription factor gene of a bHLH family, a preparation method of the adult stem cell line, a composition for the prevention or treatment of neurological diseases comprising the adult stem cell line, and a method for treating neurological diseases comprising the step of administering the composition to a subject having neurological diseases or suspected of having neurological diseases. The adult stem cells according to the present invention, which are introduced with an HGF gene and a neurogenic transcription factor gene of a bHLH family, can be used to overcome chronic impairment caused by cell death following stroke. Thus, the adult stem cells can be developed as a novel therapeutic agent or widely used in clinical trial and research for cell replacement therapy and gene therapy that are applicable to neurological diseases including Parkinson's disease, Alzheimer disease, and spinal cord injury as well as stroke.

摘要翻译： 本发明涉及导入了bHLH家族的HGF基因和神经原性转录因子基因的成体干细胞系，成体干细胞系的制备方法，用于预防或治疗神经疾病的组合物，其包含成人干细胞 细胞系和治疗神经疾病的方法，所述方法包括将所述组合物给予患有神经疾病或疑似患有神经疾病的受试者的步骤。 引入了HGF基因和bHLH家族的神经原性转录因子基因的根据本发明的成体干细胞可用于克服由中风后细胞死亡引起的慢性损伤。 因此，成人干细胞可以作为新型治疗药物开发，或广泛应用于细胞替代治疗和基因治疗的临床试验和研究，适用于帕金森病，阿尔茨海默病，脊髓损伤以及中风等神经系统疾病 。